
January 2023 guidance from FDA on dosages in oncology provides further context on expectations with Project Optimus.
January 2023 guidance from FDA on dosages in oncology provides further context on expectations with Project Optimus.
How the use of M&S in cancer trials from the outset can help address those critical “what if?” scenarios and accelerate oncology drug development.
Published: April 24th 2023 | Updated:
Published: September 1st 2018 | Updated: